Quantum leap healthcare collaborative announces result of oral paclitaxel in combination with a pd-1 and carboplatin from i-spy2 trial at asco

San francisco , may 1, 2023 /prnewswire/ -- quantum leap healthcare collaborative (quantum leap) and athenex, inc. (nasdaq: atnx) will present the findings of the i-spy 2 trial evaluation of athenex's oral paclitaxel plus encequidar in combination with gsk's dostarlimab in the neoadjuvant setting at this year's american society of clinical oncology (asco) conference. athenex, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions collaborated with gsk and quantum leap in two study arms of the i-spy 2 trial.
ATNX Ratings Summary
ATNX Quant Ranking